What question did this study set out to answer?

To assess the stability of ADAMTS13 activity in liquid plasma and its clinical implications for thrombotic thrombocytopenic purpura (iTTP).

December 8, 2025BloodOpen Access

Stability of ADAMTS13 activity in liquid plasma and its clinical application in therapeutic plasma exchange for thrombotic thrombocytopenic purpura

View Full Paper

Ask AI

Bookmark

Authors

Clinical trial confirms therapeutic plasma exchange with liquid plasma preserves ADAMTS13, reducing risks in iTTP treatment.

To assess the stability of ADAMTS13 activity in liquid plasma and its clinical implications for thrombotic thrombocytopenic purpura (iTTP).
Collected liquid plasma and thawed plasma samples at specified intervals for ADAMTS13 activity testing.
Conducted a retrospective review of iTTP patients treated with either liquid plasma and thawed plasma or thawed plasma alone.
Statistical analyses performed using Student's t-test and Fisher's exact test.
ADAMTS13 activity in liquid plasma was stable over a 26-day shelf-life period.
No significant differences were found in coagulopathy and mortality between the treatment groups.
Liquid plasma can be an effective adjunct in therapeutic plasma exchange for iTTP.

Cao et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark